Phibro Animal Health Corporation
Phibro Animal Health Corporation (PAHC) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
pahc · pe ratio · data through Jun 30, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Phibro Animal Health Corporation (PAHC) measures how much investors pay for each dollar of the company's trailing earnings. PAHC's current PE ratio of 13.49x is calculated by dividing its stock price of $31.76 by its TTM earnings per share of $2.35. −81.3% discount vs 5Y avg 72.3x
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-06-30
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 15 fiscal years · Front-end computedMinQ1 · 25%22.7x
MedianQ3 · 75%299.8x
Max
At 13.49x, PAHC's current P/E is lower than in 7% of its annual fiscal year readings over the past 15 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Drug Manufacturers - Specialty & Generic · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Phibro Animal Health CorporationYou PAHC | $1.3B | 13.49x | -48.8% | $2.35 |
 Alvotech ALVO | $1.3B | 51.30x | +94.9% | $0.10 |
 ANI Pharmaceuticals, Inc. ANIP | $1.8B | 20.21x | -23.2% | $3.91 |
 Aurinia Pharmaceuticals Inc. AUPH | $2.0B | 7.46x | -71.7% | $2.14 |
 Avadel Pharmaceuticals plc AVDL | $2.1B | N/A | — | -$0.51 |
 BGM Group Ltd. BGM | $64M | N/A | — | -$0.20 |
 Evotec SE EVO | $998M | N/A | — | -$0.28 |
Industry Average 3 peers with valid PE | — | 26.32x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-06-30Latest FY2025 | 21.43x | $1.19 | -92.5% | |
2024-06-30 FY2024 | 285.67x | $0.06 | +1578.6% | |
2023-06-30 FY2023 | 17.02x | $0.81 | +8.0% | |
2022-06-30 FY2022 | 15.76x | $1.21 | -26.7% | |
2021-06-30 FY2021 | 21.51x | $1.34 | -32.2% | |
2020-06-30 FY2020 | 31.71x | $0.83 | +35.7% | |
2019-06-30 FY2019 | 23.36x | $1.35 | -18.1% | |
2018-06-30 FY2018 | 28.52x | $1.61 | +25.9% | |
2017-06-30 FY2017 | 22.65x | $1.64 | +155.5% | |
2016-06-30 FY2016 | 8.87x | $2.10 | -64.8% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Phibro Animal Health Corporation (PAHC) measures how much investors pay for each dollar of the company's trailing earnings. PAHC's current PE ratio of 13.49x is calculated by dividing its stock price of $31.76 by its TTM earnings per share of $2.35.
Frequently asked questions
PAHC pe ratio · 6 questionsPAHC's current PE ratio is 13.49x as of 2026-06-08, based on a stock price of $31.76 and TTM EPS of $2.35. Data sourced from Financial Modeling Prep via PAHC's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Phibro Animal Health Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08